FDA Approves RHA Redensity Eye for Undereye Hollowing

On August 27, 2026, the FDA approved RHA Redensity Eye for correcting moderate to severe infraorbital volume loss and hollowing in adults aged 22 years or older, giving injectors a specialized hyaluronic acid filler specifically engineered to handle the delicate and highly dynamic undereye area. This expansion of the Teoxane RHA Collection addresses a historically tricky zone where traditional, stiffer fillers often look unnatural during facial movement or cause delayed swelling.

The FDA approval is supported by a 52-week clinical study where 93 percent of participants demonstrated aesthetic improvements at 3 months. Crucially for patient satisfaction and clinic margins, these results lasted up to 12 months without requiring touchups. The formulation is designed to mimic natural tissue movement, relying on high stretch and spreadability to integrate smoothly into the thin periorbital skin.

For your practice, this provides a predictable, on-label tool for one of the most highly requested yet challenging treatment areas, particularly as more patients seek correction for facial volume loss associated with GLP-1 receptor agonists. Instead of relying on off-label products that carry higher risks of migration or the Tyndall effect, you can now offer a dedicated option with solid longevity data. It is worth contacting your Revance representative to discuss pricing and training timelines so you can integrate this into your upcoming clinical offerings.

Source: Healio Dermatology, https://www.healio.com/news/dermatology/20260828/fda-approves-rha-redensity-eye-for-infraorbital-hollows